H19 and myocardial infarction: Furthermore, Huang et al. demonstrated that atorvastatin-pretreated mesenchymal stem cells (MSCs) facilitate angiogenesis and cardiomyocyte survival in myocardial infarction (MI) hearts by upregulating lncRNA H19 and its release via exosomes [86].